Supplements

Lipophilic agents exhibit increased volumes of distribution with risk of accumulation in patients with obesity

The paper reports that excess adiposity induces drug-specific alterations in distribution, with lipophilic agents showing increased volumes of distribution and a consequent risk of accumulation. This finding is based on a review of recent pharmacokinetic data in perioperative patients with obesity.

Last updated: Jul 7, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score32/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Perioperative drug pharmacokinetics in patients with obesity.

observational

Rousseleau D, De Baerdemaeker L · Current opinion in clinical nutrition and metabolic care (2026)

Participants: N/A
Duration: N/A
Intervention: Review of perioperative pharmacokinetics in patients with obesity
Outcome: Volume of distribution and risk of accumulation for lipophilic anesthetic agents
Effect Size: N/A
Population: Patients with obesity undergoing perioperative care

Result:

PubMed: 41995285DOI: 10.1097/MCO.0000000000001225

Mechanism Graph

Excess adiposity alters body composition and organ function
↓
Lipophilic drugs distribute into adipose tissue
↓
Increased adipose mass leads to larger volume of distribution
↓
Result: Higher risk of drug accumulation and prolonged effects

Limitations

  • ⚠The paper is a review, not a primary study, so effect sizes and specific numerical data are not provided
  • ⚠Pharmacokinetic evidence remains limited for several commonly used drugs (e.g., ketamine, magnesium sulfate, dexamethasone) in this population

Frequently Asked Questions

Why do lipophilic drugs accumulate more in obese patients?▼

Lipophilic drugs distribute into adipose tissue, and because obese patients have a higher proportion of body fat, the volume of distribution increases, leading to a greater risk of drug accumulation and prolonged effects.

What are examples of lipophilic agents mentioned in the paper?▼

The paper mentions remimazolam, ciprofol, and intravenous lidocaine as lipophilic agents studied in patients with obesity.

Does the paper recommend specific dosing adjustments for obese patients?▼

The paper advises an individualized approach based on pharmacokinetic principles and clinical titration, but does not provide specific dosing recommendations due to limited evidence for many drugs.

What is the main challenge in dosing drugs for obese patients?▼

The main challenge is that obesity alters drug distribution, clearance, and elimination in a drug-specific manner, making standard dosing strategies based on total body weight potentially unsafe.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Rousseleau D, De Baerdemaeker L. "Perioperative drug pharmacokinetics in patients with obesity.." Current opinion in clinical nutrition and metabolic care, 2026. PMID: 41995285 DOI: 10.1097/MCO.0000000000001225
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.